MedTrace Logo

The Culture of Ovarian Cancer Organoids and Drug Screening

NCT04768270 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2023-08-31

No results posted yet for this study

Summary

The tumor organoids platform can provide the precise genetic information and phenotype, as well as the heterogeneity of the tumor, thus provide information on drug sensitivity specific to the patient.This is an exploratory research to see if organoids testing could help guide precision treatment for ovarian cancer(OC) patients.

Conditions

Interventions

OTHER

no intervention

It is an observation trial.

Sponsors & Collaborators

  • Chongqing University Cancer Hospital

    lead OTHER

Principal Investigators

  • Dongling Zou, M.D. · Chongqing University Cancer Hospital

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-12
Primary Completion
2023-12-31
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04768270 on ClinicalTrials.gov